GLOBAL BRONCHITIS TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)
Global bronchitis treatment market is estimated to be valued at USD 8.22 Bn in 2024 and is expected to reach USD 11.81 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.
Discover market dynamics shaping the industry: Request sample copy
Global bronchitis treatment market is expected to witness steady growth over the forecast period, owing to increasing respiratory diseases globally due to growing pollution levels and changing lifestyle. Heavy smoking is also widely accepted as one of the primary causative factors for both acute and chronic bronchitis. Rising pollution levels in urban areas have significantly contributed to the increase in respiratory ailments. Moreover, technology advancements have led to new product developments in recent years. Various drugs and devices are being introduced for effective treatment of bronchitis. However, lack of awareness regarding bronchitis in some developing nations can hamper the market growth in the near future.
Market Driver – Growing Cases of Smoking-Induced Bronchitis
Global bronchitis treatment market growth is driven by rising number of cases of smoking-induced bronchitis. Tobacco smoking has been established as the primary cause of the two main types of bronchitis—acute bronchitis and chronic bronchitis. When a person smokes, the cilia or hair-like structures in the bronchial tubes get damaged due to the toxic chemicals in the smoke. This damage leads to reduced functioning of the cilia in clearing out mucus and foreign particles from the lungs. Thus, smokers are more prone to develop bronchitis, in which the bronchial tubes get inflamed and swollen. Chronic bronchitis has seen a rise in prevalence rates due to long-term smoking habits. The condition is marked by a cough that produces mucus most days of the month for at least three months of the year for two successive years. According to studies, around 9 out of 10 cases of chronic bronchitis can be attributed to cigarette smoking. With smokers accounting for over 1.1 billion individuals worldwide currently and the numbers estimated to rise further, there will be huge burden of smoking-related respiratory illnesses like chronic bronchitis, and this will boost demand for bronchodilators, cough suppressants, antibiotics and other bronchitis medications and therapies. Eefforts towards smoking cessation programs can also curb the impact of this driver.
Get actionable strategies to beat competition: Request sample copy
Increasing Air Pollution Worldwide
Increasing air pollution worldwide can drive the global bronchitis treatment market growth. As per World Health Organization (WHO), around 7 million people die every year due to air pollution exposure globally. Air pollution is one of the leading causes of chronic respiratory diseases like bronchitis, which damages the lungs over a long period of exposure to polluted air. Bronchitis causes inflammation in the bronchial tubes of lungs which leads to coughing, wheezing and shortness of breath.
Rising vehicular and industrial emission levels have tremendously deteriorated the air quality across major cities worldwide. According to the data from IQAir's 2021 World Air Quality Report, India had the highest annual average particulate matter (PM2.5) levels among the most polluted countries in the world. PM2.5 can easily enter deep into lungs and bloodstream, thus, increasing the risk of bronchitis and other lung diseases. China also witnessed sharp rise in air pollution levels post COVID lockdowns with most cities reporting unhealthy and hazardous air quality on daily basis. The growing population, urbanization and climate change has augmented the ground level ozone and other harmful pollutants concentration in the atmosphere. This surge in air pollution has led to exponential growth in bronchitis patient base worldwide. According to a study published by Global Asthma Network, Bangladesh witnessed over 50% increase in moderate to severe asthma cases among adults from 2010 to 2018, mostly attributed to air pollution. Rising disease incidence has boosted demand for bronchitis diagnostics, therapeutics and symptom management products globally. The market is witnessing increased adoption of combination therapies involving corticosteroids, antibiotics and bronchodilators.
Key Takeaways from Analyst:
Global bronchitis treatment market growth is driven by growing geriatric population who are more prone to chronic respiratory diseases such as bronchitis. Changing lifestyle habits with rising pollution levels and increasing smoking prevalence also contribute to rising incidence of acute bronchitis cases globally. Advances in drug delivery systems and the development of combination therapies can provide new opportunities for the market players. Lack of disease-specific drugs and high reliance on generic medications to treat bronchitis symptoms can hamper the market growth. Adherence to medication and lifestyle changes post-treatment can also pose challenge. Among region, the market will be dominated by developed economies due to higher awareness and healthcare expenditure. Meanwhile, developing Asian countries will form the most lucrative market area owing to their large patient pools and improving access to healthcare.
Bronchitis treatment landscape will evolve with greater focus on preventing exacerbations and addressing the root causes. Telehealth and remote monitoring solutions can potentially boost medication adherence. Further research into pathogenic factors and novel drugs targeting different disease indications can drive the market growth.
Market Challenges: High cost of advanced treatments
The high cost of advanced bronchitis treatments can hamper the global bronchitis treatment market growth. Bronchitis is a common respiratory condition that involves inflammation of the bronchial tubes that carry air to and from the lungs. While most cases are acute and can be treated with over-the-counter medication, chronic bronchitis often requires more intensive treatment and management over a longer period. Advanced treatments for chronic bronchitis like bronchodilators, steroids, antibiotics, and oxygen therapy involve costly prescription drugs and administration by medical professionals. This makes such treatments highly inaccessible for a large section of global population with low or middle incomes. According to the data from World Bank in 2020, more than 40% of the global population lived on less than US$ 5.50 per day. For them, even basic treatment costs can be financially burdensome. This significantly restricts their ability to regularly opt for more advanced bronchitis interventions. High treatment expenses also discourage patients from continuing the recommended course of medication. Inability to fully comply with prescribed therapy protocols leads to exacerbation of symptoms and increased healthcare utilization in future. This has major economic implications for patients as well as for countries' public healthcare budgets. Studies show that nearly 50% of chronic bronchitis patients in the U.S. do not continue medication beyond initial prescriptions due to costs.
Market Opportunities: Growing focus on telemedicine and digital health solutions
Global bronchitis treatment market can witness significant growth opportunities due to growing focus on telemedicine and digital health solutions. With the COVID-19 pandemic highlighting the importance of virtual care, telemedicine is expected to play a central role in how healthcare is delivered for chronic conditions like bronchitis. Telemedicine offers convenience and ease of access to patients, allowing them to consult with doctors and receive routine checkups without having to physically visit an healthcare facility. This reduces disease transmission risk as well as saves travel time and costs for patients. Many healthcare systems across the world have also upgraded their infrastructure to support tele/digital health amid the pandemic. For example, the European Commission has deployed over €200 million to support telemedicine scale-up in European Union countries from 2021-2022. This funding is aimed at boosting virtual care collaboration between EU hospitals and encouraging nationwide telehealth networks. In the U.S., the Centers for Medicare and Medicaid expanded telehealth coverage and reimbursement in 2021. This policy change resulted in telehealth usage increasing by 154% from 2019 to 2020, according to the U.S. Department of Health and Human Services. Such supportive regulations and investments in virtual care technologies offer lucrative opportunities for bronchitis treatment and management through digital channels. Telemedicine can play a vital role in remote patient monitoring, medication management, quick diagnosis and guiding lifestyle changes.
Discover high revenue pocket segments and roadmap to it: Request sample copy
By Type- Rising prevalence of air pollution drives acute bronchitis segment growth
In terms of type, acute bronchitis segment is estimated to contribute the highest market share of, owing to factors such as rising prevalence of air pollution globally. Acute Bronchitis is caused by viral or bacterial infections and develops rapidly over a short period, usually preceded by a cold or the flu. The condition is often seen as the lower respiratory tract tries fighting off an infection. In many parts of the world, air pollution levels have risen significantly over the past few decades due to rapid industrialization and urbanization. Long-term exposure to traffic fumes, cigarette smoke and other outdoor pollutants weakens the immune system and damages the protective lining of the lower respiratory tract, making people more susceptible to acute bronchitis. Regions with heavy smog or high concentrations of particulate matter tend to record a higher incidence of acute bronchitis. This can boost demand for drugs and therapies to treat flare-ups of the condition. Lack of adequate pollution control in developing nations also contributes to growing acute bronchitis patient pool globally.
By Treatment- Popularity of oral medications boosts drugs segment growth
In terms of treatment, drugs segment is estimated to contribute the highest market share of, owing to factors such as popularity and convenience of oral medications for bronchitis. While oxygen therapy provides immediate relief for breathlessness, drugs continue to be the most effective long-term treatment strategy for both acute and chronic bronchitis. A wide range of antibiotics, cough suppressants, expectorants and anti-inflammatory drugs are available in oral pill or liquid form, making adherence very convenient compared to nebulizers or inhalers. Most treatment guidelines also recommend a course of drugs before other therapies. The oral route has more affordable options as well. This has ensured that drugs remain the first line of defense for the majority of bronchitis patients.
By Drug Class- Wide usage in COPD treatment drives anti-inflammatory drugs segment growth
In terms of drug class, anti-inflammatory drugs segment is estimated to contribute the highest market share of, owing to factors such as its widespread usage in COPD treatment protocols. Chronic bronchitis often occurs simultaneously with emphysema in COPD patients. Persistent inflammation in the lower airways is a hallmark of both these conditions. As a result, anti-inflammatory medicines play a pivotal role in the long-term management of chronic bronchitis symptoms. A variety of corticosteroids and other novel anti-inflammatory entities are routinely prescribed to quell symptoms and reduce flare-ups. Given the high prevalence of COPD globally, these drugs see vast consumption. Certain anti-inflammatory drugs also help shorten recovery from acute bronchitis episodes by mitigating the inflammatory response. This extensive, multi-purpose utility of anti-inflammatory drugs has helped boost their uptake.
To learn more about this report, Request sample copy
North America dominates the global bronchitis treatment market with an estimated market share of 38.2% in 2024. With the presence of leading pharmaceutical companies and advanced healthcare infrastructure, North America enjoys high availability of effective bronchitis drugs and medical devices. The region has a culture of preventive healthcare and rising health awareness among population that drives early treatment seeking behavior for lung conditions like bronchitis.
Stringent regulatory guidelines ensure highest quality standards are met by drug manufacturers before approval and marketing in the region. This has earned customers' trust in native bronchitis products over years. Furthermore, the availability of private health insurance and favorable reimbursement policies make treatments highly accessible in North America. Leading medical device brands from the U.S. and Canada also offer a wide range for bronchitis pulmonary therapy with varied pricing options.
Asia Pacific region presents the fastest growing bronchitis treatment market. Countries like China and India are witnessing economic prosperity and improved access to healthcare. Rising disposable incomes allow customers to spend more on respiratory illness treatment. Also, governments are focusing on developing healthcare infrastructure in rural regions.
This attracts many international pharmaceutical companies to either set up local manufacturing plants or enter strategic partnerships with domestic drug makers for bronchitis medications. Increasing awareness about lifestyle diseases and benefits of early treatment drives the market growth
Global Bronchitis Treatment Market Report Coverage
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 8.22 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 5.3% | 2031 Value Projection: | US$ 11.81 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, Merck & Co., Pfizer, Teva Pharmaceutical Industries, Sanofi, Roche, Johnson & Johnson, Mylan N.V., Gilead Sciences, AbbVie, Bausch Health Companies, Hikma Pharmaceuticals, Amgen, Sumitomo Dainippon Pharma, Eli Lilly and Company |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
*Definition: Global Bronchitis Treatment Market involves developing and providing drugs, medical devices, vaccines and other treatment options for acute and chronic bronchitis on a global scale. Key players in this market focus on research and development of new therapies and medications to treat symptoms, prevent exacerbations, and improve quality of life for patients suffering from both forms of this inflammatory lung disease worldwide. The goal is to expand treatment accessibility and clinical efficacy through international research, clinical trials, manufacturing, and distribution of bronchitis treatments.
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Credibility and Certifications
860519526
9001:2015
27001:2022
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowSelect a License Type
Credibility and Certifications
860519526
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 